Loading market dashboard
TriSalus Life Sciences, Inc.
TLSIHealthcareNASDAQUS
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
ATLANTA, June 05, 2026 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether TriSalus Life Sciences, Inc. (“TriSalus” or the “Company”) (NASDAQ: TLSI) complied with federal securities laws. On May 12, 2026, TriSalus reported its first quarter 2026 financial results, revealing a decrease in revenue compared to the same period in 2025 and lowered its full year revenue guidance. The price of the Company's stock dropped following this news.
NEW YORK, June 4, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of TriSalus Life Sciences Inc. ("TriSalus" or the "Company") (NASDAQ: TLSI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
LOS ANGELES--(BUSINESS WIRE)---- $TLSI--TLSI Investors Have Opportunity to Join TriSalus Life Sciences, Inc. Fraud Investigation with the Schall Law Firm.
NEW YORK, June 02, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of TriSalus Life Sciences Inc. (“TriSalus” or the “Company”) (NASDAQ: TLSI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
New York, New York--(Newsfile Corp. - May 25, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into TriSalus Life Sciences, Inc. ("TriSalus Life Sciences, Inc.") (NASDAQ: TLSI) concerning potential violations of the federal securities laws. TLSI reported Q1 2026 revenue of $8.9 million.
TriSalus Life Sciences Inc. reaffirmed $60-$62 million revenue guidance on March 5, 2026. Months later, the company cut that outlook to $54-$57 million after missing Q1 estimates.
[url="]Glancy Prongay Wolke and Rotter LLP[/url], a leading national shareholder rights law firm, today announced that it has commenced an investigation on behal
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of TriSalus Life Sciences Inc. (“TriSalus” or the “Company”) (NASDAQ: TLSI) investors concerning the Company's possible violations of the federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON TRISALUS LIFE SCIENCES INC. (TLSI), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS.
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of TriSalus Life Sciences Inc. (“TriSalus” or the “Company”) (NASDAQ: TLSI) investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN TRISALUS LIFE SCIENCES INC. (TLSI), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. Contact the Law Offices of Howard G. Smith to discuss your.
New York, New York--(Newsfile Corp. - May 19, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into TriSalus Life Sciences, Inc. ("TriSalus Life Sciences, Inc.") (NASDAQ:TLSI) concerning potential violations of the federal securities laws. TLSI reported Q1 2026 revenue of $8.9 million.
NEW YORK--(BUSINESS WIRE)--Shareholders who held TriSalus Life Sciences Inc. (TLSI) stock lost money after the company cut its full-year 2026 revenue guidance to $54 million-$57 million, down from the $60 million-$62 million range reaffirmed approximately two months earlier on March 5, 2026. Those who purchased TLSI shares and suffered losses are encouraged to submit their information to Levi & Korsinsky. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by t.
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of TriSalus Life Sciences Inc. (“TriSalus” or the “Company”) (NASDAQ: TLSI) on behalf of investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON TRISALUS LIFE SCIENCES INC. (TLSI), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS. What Is The Investigation About? On May 12, 2026, TriSalus reported first quarter.
New York, New York--(Newsfile Corp. - May 14, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into TriSalus Life Sciences, Inc. ("TriSalus Life Sciences, Inc.") (NASDAQ: TLSI) concerning potential violations of the federal securities laws. TLSI reported Q1 2026 revenue of $8.9 million.
TriSalus Life Sciences NASDAQ: TLSI reported slightly lower first-quarter revenue and reduced its full-year 2026 revenue outlook, citing disruption from a broad commercial reorganization and a delayed FDA review for its next-generation TriNav Advance device.
TriSalus Life Sciences, Inc. (TLSI) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to a loss of $0.33 per share a year ago.
DENVER--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announced financial results for the quarter ended March 31, 2026, and provided an operational update. “The first quarter marked an important strategic inflection point for TriSalus as we significantly strengthened our c.
WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announced the publication of the largest real-world evidence study to date evaluating the clinical and economic impact of Pressure-Enabled Drug Delivery (PEDD®) technology used in trans-arterial chemoemboliz.
WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announced the initiation of patient enrollment for the PREDICTT clinical trial (NCT07444645), a prospective study designed to evaluate its novel Pressure-Enabled Drug Delivery™ (PEDD™) approach in patients w.
WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, announced today that it will host a conference call and webcast on Tuesday, May 12, 2026 at 4:30 PM eastern time to discuss its financial results for the quarter ended March 31, 2026. A press release detailing the.
WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announced its participation in the Society of Interventional Radiology (SIR) 2026 Annual Scientific Meeting, taking place April 11–15, 2026, in Toronto, Ontario, Canada. TriSalus will showcase new clinical a.
WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announces the appointment of Richard Marshall, M.D., as Chief Medical Officer on a full-time basis, effective June 29, 2026. Dr. Marshall will transition into the role from his current position as Medical Di.
TriSalus Life Sciences, Inc. (NASDAQ: TLSI - Get Free Report) CEO Mary Szela sold 4,358 shares of the firm's stock in a transaction on Wednesday, March 11th. The shares were sold at an average price of $4.13, for a total value of $17,998.54. Following the completion of the transaction, the chief executive officer owned 768,931 shares
DENVER--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announced the publication of preclinical research evaluating Pressure-Enabled Drug Delivery™ (PEDD™) of nelitolimod in liver tumor models in Frontiers in Oncology. The study evaluated the delivery and biologic activity.
